Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.12.004Source: DataRank Database

Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor is a research paper published in Journal of Cystic Fibrosis (2021). On theSindex it has a DataRank of 0. It has been cited 82 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access82 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 5.21)OA: greenTopics (75)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Christopher N. Fortner ORCID,Amanda Cotey,Charles R. Esther ORCID,Aaron Trimble ORCID,Bethany Collins

Live enrichment

PubMed:34952795 OpenAlex:https://openalex.org/W4200001023

National Heart, Lung, and Blood Institute

Grant: P01 HL108808

National Heart, Lung, and Blood Institute

Grant: P30-DK065988

National Institute of Environmental Health Sciences

Grant: P30-ES10126

Cystic Fibrosis Foundation

Grant: RDP R026-CR11

Cystic Fibrosis Foundation

Grant: TRIMBL19AC0

National Institutes of Health

Grant: 5P30ES010126-11

UNC-CH Center for Environmental Health and Suscesptibility

National Institutes of Health

Grant: 5P01HL108808-08

Development of Novel Mycolytic Therapies for Lung Disease

NIDDK NIH HHS

Grant: P30 DK065988

NIEHS NIH HHS

Grant: P30 ES010126

NHLBI NIH HHS

Grant: T32 HL007106

FWCI

5.21

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: Elsevier Non-Commercial

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9213569

publisherhttps://api.elsevier.com/content/article/PII:S1569199321021615?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1569199321021615?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jcf.2021.12.004

Fields of Study

Cystic Fibrosis Research AdvancesNeonatal Respiratory Health ResearchBreastfeeding Practices and Influences0301 basic medicine03 medical and health sciences0302 clinical medicineAdultAminophenolsBenzodioxolesChloride Channel AgonistsCystic FibrosisDrug CombinationsFemaleHumansIndolesInfantMaternal ExposureMothersPlacentaPregnancyPyrazolesPyridinesPyrrolidinesQuinolones

MeSH Terms

AdultAminophenolsCystic FibrosisDrug CombinationsFemaleHumansIndolesInfantMothersPlacentaPregnancyPyrazolesPyridinesPyrrolidinesQuinolonesMaternal ExposureBenzodioxolesChloride Channel Agonists

Keywords

IvacaftorMedicineCord bloodPregnancyBreast milkDrugNewborn screeningCystic fibrosisPhysiologyObstetricsInternal medicinePediatricsPharmacologyCystic fibrosis transmembrane conductance regulatorGeneticsAdultIndolesPyrrolidinesPyridinesPlacentaInfantMothersQuinolonesAminophenolsDrug CombinationsMaternal ExposureHumansPyrazolesFemaleBenzodioxolesChloride Channel AgonistsElexacaftorTezacaftor

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Related Papers (1)

Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI

N/A

4.1DataRank · unranked

Journal of Cystic Fibrosis(2022)

co-citedsame journal

10.1016/j.jcf.2022.10.003